

Web references [posted as supplied by author]

w1 Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *JAMA*. 2001;286:1869-1878.

w2 Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. *Intensive Care Med*. 1998;24:663-672.

w3 Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. *Blood Coagul Fibrinolysis*. 2006;17:521-526.

w4 Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, et al; BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. *Semin Thromb Hemost*. 2003;29:645-652.

w5 Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. *Thromb Haemost*. 2000;84:583-590.

w6 Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. *Thromb Haemost*. 2003;90:235-244.

w7 Balk RA, Bedrossian C, McCormick L, Baughman J, Eisele B, Keinecke HD, et al. Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. *Intensive Care Med*. 1995; 21(suppl 1):S17.

w8 Korninger C, Klepteko W, Miholic J, Schwarz C, Lechner K. Randomized trial of Antithrombin-III versus placebo in patients undergoing peritoneo-venous shunt operation. *Thromb Haemost*. 1987;58:426.

w9 Muntean W, Rosegger H. Antithrombin III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract). *Thromb Haemost*. 1989; 62: 288.

w10 Palareti G, Leganani C, Coccheri S, Ridolfi L, Baudo F, Caimi TM, et al. Laboratory Effects Of Antithrombin-III (ATIII) Replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support - A controlled, double-blind, randomized multicenter study. *Thromb Haemost*. 1995;73:1251.

w11 Paternoster DM, De Fusco D, Tambuscio B. Treatment with antithrombin III (AT III) concentrate in pre-eclampsia. *Int J Gynaecol Obstet*. 2000;71:175-176.

w12 Schuster HP, Eisele B, Keinecke HO, Heinricks H, Mescheder A, Knaub S. A-AT III study: Antithrombin III in patients with sepsis. *Intensive Care Medicine*. 1997; 23(suppl 1):S76.

w13 Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, et al; KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. *Thromb Haemost*. 2006;95:850-856.

w14 Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blomback M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. *Acta Anaesthesiol Scand*. 1992;36:745-752.

w15 Baudo F, DeGasperis A, deCataldo F, Caimi TM, Cattaneo D, Redaelli R, et al. Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. *Thromb Res*. 1992;68:409-416.

w16 Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. *Intensive Care Med*. 1998;24:336-342.

w17 Diaz-Cremades JM, Lorenzo R, Sanchez M, Moreno MJ, Alsar MJ, Bosch JM, et al. [Use of antithrombin III in critical patients](#). *Intensive Care Med*. 1994;20:577-580.

w18 Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. *Chest*. 1993;104:882-888.

- w19 Fulia F, Cordaro S, Meo P, Gitto P, Gitto E, Trimarchi G, et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? *Biol Neonate*. 2003;83:1-5.
- w20 Grenander A, Bredbacka S, Rydvall A, Aroch R, Edner G, Koskinen LO, et al. Antithrombin Treatment in Patients With Traumatic Brain Injury. *J Neurosurg Anesthesiol*. 2001;13:49-56.
- w21 Haire WD, Ruby EI, Stephens LC, Reed E, Tarantolo SR, Pavletic ZS, et al. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 1998;4:142-1450.
- w22 Harper PL, Williamson L, Park G, Smith JK, Carrell RW. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. *Transfus Med*. 1991;1:121-128
- w23 Inthorn D, Hoffmann JN, Hartl WH, Muhlbaier D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. *Shock*. 1997;8:328-334.
- w24 Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. *J Hepatol*. 1993;17:326-331.
- w25 Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. *Am J Respir Crit Care Med*. 1998;158:470-476.
- w26 Schorr M, Siebeck M, Zugel N, Welcker K, Gippner-Steppert C, Czwienczek E, et al. Antithrombin III and local serum application: adjuvant therapy in peritonitis. *Eur J Clin Invest*. 2000;30:359-366.
- w27 Smith-Erichsen N, Aasen AO, Kongsgaard UE, Bakke A, Bergan A, Bjerkelund CE, et al. The effect of antithrombin III substitution therapy on components of the plasma protease systems in surgical patients. *Clin Intensive Care*. 1996;7:291-296.
- w28 Waydhas C, Nast-Kolb D, Gippner-Steppert C, Trupka A, Pfundstein C, Schweiberer L, et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. *J Trauma*. 1998;45:931-940.
- w29 Banfi R, Borselli G, Giannelli P, Marinai C, Ruffino I. Antithrombin III use in intensive care units. *J Appl Ther*. 1996;1:179-183.
- w30 Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. *Thromb Res*. 1985;39:81-89.
- w31 Brangenberg R, Bodensohn M, Burger U. Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters. *Biol Neonate*. 1997;72:76-83.
- w32 Danielsson P, Nilsson L, Nettelblad H, Sjoberg F.. Is there a need for antithrombin III substitution early after burn injury? *Burns*. 1997;23:300-305.
- w33 du Cheyron D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study. *Critical Care*. 2006;10:R45.
- w34 Fertmann JM, Wimmer CD, Arbogast HP, Illner WD, Tarabichi A, Calasan I, et al. Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis. *Transpl Int*. 2006;19:458-465.
- w35 Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A, et al. Meningococemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. *Intensive Care Med*. 1990;16:121-124.
- w36 Hanada T, Abe T, Takita H. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. *Am J Pediatr Hematol Oncol*. 1985;7:3-8.
- w37 Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. *Haematologica*. 2006;91:795-800.

- w38 Hellgren M, Javelin L, Hagnevik K, Blomback M. Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. *Thromb Res.* 1984;35:459-466.
- w39 Hoffmann JN, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. *Crit Care Med.* 2004;32:1851-1859.
- w40 Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, et al. Antithrombin III in patients with severe sepsis: a pharmacokinetic study. *Intensive Care Med.* 2000;26:704-715.
- w41 Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of Antithrombin III supplementation on inflammatory response in patients with severe sepsis. *Shock.* 1998;10:90-96.
- w42 Jochum M. Influence of high-dose antithrombin concentrate therapy on the Release of Cellular Proteinases, Cytokines, and Soluble Adhesion Molecules in Acute Inflammation. *Seminars in Hematology;* 1995;32(4, Suppl 2):19-32.
- w43 Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al; KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. *J Thromb Haemost.* 2006;4:90-97.
- w44 Kowal-Vern A, McGill V, Walenga JM, Gamelli RL. Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. *J Burn Care Rehabil.* 2000;21:115-127.
- w45 Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. *Clin Pharmacol Ther.* 2006;79:23-34.
- w46 Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K, et al. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial. *Gynecol Obstet Invest.* 1987;23:230-240.
- w47 Messori A, Vacca F, Vaiani M, Trippoli S; Gruppo di Studio sull'antitrombina III. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. *Crit Care.* 2002;6:447-451.
- w48 Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al; Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. *Cancer.* 2003;97:508-516.
- w49 Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. *Bone Marrow Transplant.* 1997;20:871-878.
- w50 Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. *Anesth Analg.* 2006;102:1007-1011.
- w51 Paternoster DM, Fantinato S, Manganelli F, Milani M, Nicolini U, Girolami A. Efficacy of AT in pre-eclampsia: a case-control prospective trial. *Thromb Haemost.* 2004;91:283-289.
- w52 Scherer R, Gille A, Erhard J, Paar D, Kox WJ. The effect of substitution with AT III- and PPSB-concentrates in patients with terminal liver insufficiency. *Anaesthesist.* 1994;43:178-182.
- w53 Scherer R, Kabatnik M, Erhard J, Peters J. The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease. *Intensive Care Med.* 1997;23:1150-1158.
- w54 Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. *Eur J Haematol.* 1989;43:22-28.

w55 Shimada M, Matsumata T, Kamakura T, Hayashi H, Urata K, Sugimachi K. Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates. *Thromb Res.* 1994;74:105-114.

w56 Terao T, Kobayashi T, Imai N, Oda Hiroyuki, Karasawa T. Pathological State of the Coagulatory and Fibrinolytic System in Preeclampsia and the Possibility of its Treatment. *Asia-Oceania J Obstet Gynaecol.* 1988;15:25-32.

w57 van Beek EJ, von der Mohlen MA, ten Cate JW, Brandjes DP, Buller HR. Antithrombin III concentrate in the treatment of DIC: a retrospective follow-up study. *Neth J Med.* 1994;45:206-210.

w58 van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. *Crit Care Med.* 2003;31:1359-1366.

w59 Vinazzer HA. Antithrombin III in shock and Disseminate Intravascular Coagulation. *Clinical Appl. Thrombosis/ Hemostasis.* 1995;1:62-65.

w60 von Kries R, Stannigel H, Gobel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. *Eur J Pediatr.* 1985;144:191-194.

w61 D'angelo A, Valsecchi L. A double blind-study of high-dose Antithrombin supplementation in early preeclampsia. *Thrombosis Research.* 2005; 115(Suppl 1):117.

w